Whitepaper: Making APAC the Oncology Clinical Trial Destination
A new whitepaper from Premier Research makes the case that the Asia-Pacific (APAC) Region is the hot spot for oncology clinical trials. Currently, APAC stands as the region with the most ongoing oncology trials worldwide, with the number of active trials growing 138% over the last 10 years. In the whitepaper, the authors break down what factors are driving this growth and why clinical research organizations (CROs) should consider hosting their trials in the region. Chief among these reasons is the massive potential patient pool.
Gilead Spends $455 Million for Rights to New Breast Cancer Drug in Asia
Hot off the heels of Gilead’s June approval for Troldelvy for metastatic triple-negative breast cancer (TNBC) drug in China, the company has agreed to a deal buying exclusive rights to sell the drug in Asia from the China-based Everest Medicines. This agreement gives Gilead global control of Troldelvy’s distribution. Gilead got the drug in its $21 billion acquisition of Immunomedics, which previously sold the rights to the drug to Everest.
Bringing Data-Enabled Healthcare to Asian-Pacific Nations
Asia-Pacific (APAC) is the most population-dense region of the world with an increasingly growing aged populace. However, substantial disparities to [...]
News Across the Globe – New Quarterly by ISPOR
ISPOR has announced the launch of its new quarterly newsletter, News Across the Globe. The newsletter covers global health policy [...]
